CY1122608T1 - Θεραπευτικη αγωγη - Google Patents

Θεραπευτικη αγωγη

Info

Publication number
CY1122608T1
CY1122608T1 CY20191101325T CY191101325T CY1122608T1 CY 1122608 T1 CY1122608 T1 CY 1122608T1 CY 20191101325 T CY20191101325 T CY 20191101325T CY 191101325 T CY191101325 T CY 191101325T CY 1122608 T1 CY1122608 T1 CY 1122608T1
Authority
CY
Cyprus
Prior art keywords
taxane
compound
relates
treatment
cancer
Prior art date
Application number
CY20191101325T
Other languages
English (en)
Inventor
Barry Robert Davies
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1122608T1 publication Critical patent/CY1122608T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ένα συνδυασμό που περιλαμβάνει το (5)-4-αμινο-Ν-(1-(4-χλωροφαινυλο)-3-υδροξυπροπυλο)-1-(7Η-πυρρολο[2,3-d]πυριμιδιν-4-υλο) πιπεριδινο-4-καρβοξαμίδιο, ή ένα φαρμακευτικά αποδεκτό άλας αυτού, στο εξής «Ένωση (I)», και μια ταξάνη. Οι ταξάνες περιλαμβάνουν εδραιωμένα φάρμακα κατά του καρκίνου όπως η ντοσεταξέλη (Taxotere™) και η πακλιταξέλη (Taxol™). Τέτοιοι συνδυασμοί μπορεί να είναι χρήσιμοι στην αγωγή ή την προφύλαξη από τον καρκίνο. Η εφεύρεση αναφέρεται επίσης σε μια φαρμακευτική σύνθεση που περιλαμβάνει μια τέτοια Ένωση (I) και μια ταξάνη. Η εφεύρεση αναφέρεται περαιτέρω σε μια μέθοδο αγωγής που περιλαμβάνει ταυτόχρονη, διαδοχική ή ξεχωριστή χορήγηση της Ένωσης (I) και μιας ταξάνης, σε ένα θερμόαιμο ζώο, όπως ο άνθρωπος. Η εφεύρεση αναφέρεται επίσης σε ένα κιτ που περιλαμβάνει την Ένωση (I) και μια ταξάνη, προαιρετικά με οδηγίες χρήσης.
CY20191101325T 2011-04-01 2019-12-17 Θεραπευτικη αγωγη CY1122608T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470668P 2011-04-01 2011-04-01
PCT/GB2012/050736 WO2012131399A1 (en) 2011-04-01 2012-04-02 Therapeutic treatment

Publications (1)

Publication Number Publication Date
CY1122608T1 true CY1122608T1 (el) 2021-03-12

Family

ID=45976963

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101325T CY1122608T1 (el) 2011-04-01 2019-12-17 Θεραπευτικη αγωγη

Country Status (26)

Country Link
US (2) US9402847B2 (el)
EP (2) EP3620159A1 (el)
JP (1) JP6080837B2 (el)
KR (1) KR101851820B1 (el)
CN (1) CN103442708B (el)
AU (1) AU2012235902B2 (el)
BR (1) BR112013025410A2 (el)
CA (1) CA2831848C (el)
CY (1) CY1122608T1 (el)
DK (1) DK2694056T3 (el)
EA (1) EA027506B1 (el)
ES (1) ES2761311T3 (el)
HR (1) HRP20191927T1 (el)
HU (1) HUE047357T2 (el)
IL (1) IL228589B (el)
LT (1) LT2694056T (el)
ME (1) ME03589B (el)
MX (1) MX357447B (el)
MY (1) MY169449A (el)
PL (1) PL2694056T3 (el)
PT (1) PT2694056T (el)
RS (1) RS59568B1 (el)
SG (1) SG193505A1 (el)
SI (1) SI2694056T1 (el)
WO (1) WO2012131399A1 (el)
ZA (1) ZA201308176B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013025410A2 (pt) * 2011-04-01 2016-12-20 Astrazeneca Ab tratamento terapêutico
CN105142629B (zh) * 2013-03-04 2018-11-23 阿斯利康(瑞典)有限公司 组合治疗
CN107670048B (zh) 2017-08-30 2019-04-26 南京明臻医药科技有限公司 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637271A (el) 1963-04-04 1900-01-01
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
AU715202B2 (en) 1996-04-03 2000-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
BRPI9810945B8 (pt) 1997-06-27 2021-05-25 Abraxis Bioscience Inc formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas
HUP0002956A3 (en) 1997-08-05 2002-01-28 Pfizer Prod Inc Use of 4-aminopyrrole[3,2d]pyrimidines for the preparation of pharmaceutical compositions treating diseases related to an excess of neuropeptide y
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
PL345906A1 (en) 1998-06-04 2002-01-14 Abbott Lab Cell adhesion-inhibiting antinflammatory compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
YU83302A (sh) 2000-06-26 2005-09-19 Pfizer Products Inc. Jedinjenja pirolo (2,3-d) pirimidina kao imunosupresivni agensi
BR0113585A (pt) 2000-08-31 2003-07-29 Hoffmann La Roche Derivados quinazolina como antagonistas adrenérgicos alfa-1
NZ525885A (en) 2000-12-01 2005-01-28 Osi Pharm Inc Compounds specific to adenosine A1, A2A, and A3 receptor and uses as ubiquitous modulators of physiological activities
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US20020182204A1 (en) * 2001-03-23 2002-12-05 Marie-Christine Bissery Combination of a taxane and a cyclin-dependent kinase
IL162884A0 (en) 2002-01-07 2005-11-20 Eisai Co Ltd Deazapurines and uses thereof
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
MEP16308A (en) * 2002-05-17 2010-06-10 Aventis Pharma Sa Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
TW200410688A (en) 2002-06-26 2004-07-01 Ono Pharmaceutical Co Therapeutics for diseases from vasoconstriction or vasodilatation
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
JP2006503826A (ja) 2002-09-06 2006-02-02 スミスクライン・ビーチャム・コーポレイション ピロロ［２，３−ｄ］ピリミジン−４−イルおよびプリン−６−イル尿素化合物
US20060159617A1 (en) 2002-11-08 2006-07-20 Ashfaq Mahmood Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors
EP1568699A4 (en) 2002-12-04 2007-08-15 Eisai R&D Man Co Ltd 1,3-DIHYDROIMIDAZOLE CONNECTION WITH CONDENSED RING
EP1444982A1 (de) 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
WO2004080463A1 (en) 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
WO2004094426A1 (en) 2003-04-21 2004-11-04 Ustav Organické Chemie A Biochemie Akademie Ved Ceské Republiky (purin-6-yl) amino acid and production method thereof
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
AU2004268621C1 (en) 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
NZ547327A (en) 2003-11-21 2009-08-28 Array Biopharma Inc AKT protein kinase inhibitors
EP1698375B1 (en) 2003-12-25 2014-04-02 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
CA2590961C (en) 2004-12-28 2013-11-26 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
FR2880626B1 (fr) 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
FR2880540B1 (fr) 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
WO2006091450A1 (en) 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
KR20080026654A (ko) 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 헤테로시클릭 야누스 키나제 3 억제제
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
ES2719093T3 (es) 2005-08-31 2019-07-08 Abraxis Bioscience Llc Composiciones de fármacos poco solubles en agua con mayor estabilidad y métodos para su preparación
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
TW200738709A (en) 2006-01-19 2007-10-16 Osi Pharm Inc Fused heterobicyclic kinase inhibitors
WO2007125315A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
JP5606734B2 (ja) 2006-04-25 2014-10-15 アステックス、セラピューティックス、リミテッド 医薬化合物
JP2009534454A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2007125325A1 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
WO2007125310A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008094321A2 (en) * 2006-10-04 2008-08-07 Universtiy Of South Florida Akt sensitization of cancer cells
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
MX2009006700A (es) 2006-12-21 2009-06-30 Vertex Pharma Derivados de 5-ciano-4-(pirolo)[2,3b]piridina-3-il)-pirimidinas utiles como inhibidores de proteina-cinasas.
NZ585261A (en) 2007-10-11 2011-10-28 Astrazeneca Ab Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors
BR112013025410A2 (pt) * 2011-04-01 2016-12-20 Astrazeneca Ab tratamento terapêutico

Also Published As

Publication number Publication date
US20160317540A1 (en) 2016-11-03
WO2012131399A1 (en) 2012-10-04
EA201391327A1 (ru) 2014-03-31
SG193505A1 (en) 2013-10-30
HRP20191927T1 (hr) 2020-01-10
US9402847B2 (en) 2016-08-02
PT2694056T (pt) 2019-11-20
EP2694056A1 (en) 2014-02-12
AU2012235902A1 (en) 2013-05-02
ES2761311T3 (es) 2020-05-19
RS59568B1 (sr) 2019-12-31
CN103442708A (zh) 2013-12-11
IL228589A0 (en) 2013-12-31
MY169449A (en) 2019-04-11
DK2694056T3 (da) 2020-01-02
ME03589B (me) 2020-07-20
KR20140022856A (ko) 2014-02-25
ZA201308176B (en) 2015-12-23
MX357447B (es) 2018-07-10
NZ616410A (en) 2015-09-25
LT2694056T (lt) 2019-12-10
CA2831848A1 (en) 2012-10-04
PL2694056T3 (pl) 2020-03-31
EP3620159A1 (en) 2020-03-11
JP2014509639A (ja) 2014-04-21
JP6080837B2 (ja) 2017-02-15
MX2013011413A (es) 2014-05-21
BR112013025410A2 (pt) 2016-12-20
IL228589B (en) 2019-09-26
SI2694056T1 (sl) 2019-12-31
CA2831848C (en) 2020-12-22
HUE047357T2 (hu) 2020-04-28
CN103442708B (zh) 2016-11-09
EA027506B1 (ru) 2017-08-31
US20140121227A1 (en) 2014-05-01
EP2694056B1 (en) 2019-10-16
AU2012235902B2 (en) 2015-08-27
KR101851820B1 (ko) 2018-06-04

Similar Documents

Publication Publication Date Title
CY1121402T1 (el) Παρασιτοκτονες συνθεσεις οι οποιες περιλαμβανουν εναν δραστικο παραγοντα ισοξαζολινης, μεθοδοι και χρησεις αυτων
CY1122608T1 (el) Θεραπευτικη αγωγη
CY1121120T1 (el) Αρυλ- ή ετεροαρυλ-υποκατεστημενες ενωσεις βενζολιου
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
BR112015016681A8 (pt) uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático
CY1117909T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει ολμεσαρτανη μεδοξομιλη και ροσουβαστατινη ή το αλας της
DOP2016000250A (es) Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa
EA201390339A1 (ru) Замещенные имидазопиридазины
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
CY1120438T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει μυο-ινοσιτολη και d-κιρο-ινοσιτολη
GT201400111A (es) Triazolopiridinas sustituidas
CR20120414A (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
EA201400311A1 (ru) Аминозамещенные имидазопиридазины
ECSP15008695A (es) Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CY1123614T1 (el) Μεθοδος θεραπειας δυσκινησιας
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
CY1119391T1 (el) Παραγωγα οξαζολιδιν-2- ονη- πυριμιδινης
CY1124316T1 (el) Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα
EA201891050A1 (ru) Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
CY1122357T1 (el) Αντικαρκινικος συνδυασμος που περιλαμβανει καμπαζιταξελη και σισπλατινη